Vaidya A, et al.. The unrecognized prevalence of primary aldosteronism. Ann Intern Med 2020; 173:683. doi: 10.7326/L20-1097

• Crossref
Vaidya A, . The unrecognized prevalence of primary aldosteronism. Ann Intern Med 2020; 173:683. doi: 10.7326/L20-109710.7326/L20-1097)| false
• Search Google Scholar
• Export Citation

Monticone S, et al.. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol 2017; 69:1811−1820. doi: 10.1016/j.jacc.2017.01.052

• Crossref
Monticone S, . Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol 2017; 69:1811−1820. doi: 10.1016/j.jacc.2017.01.05210.1016/j.jacc.2017.01.052)| false
• Search Google Scholar
• Export Citation

Paolo Rossi G, et al.. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48:2293−2300. doi: 10.1016/j.jacc.2006.07.059

• Crossref
Paolo Rossi G, . A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48:2293−2300. doi: 10.1016/j.jacc.2006.07.05910.1016/j.jacc.2006.07.059)| false
• Search Google Scholar
• Export Citation

Calhoun DA, et al.. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40:892−896. doi: 10.1161/01.hyp.0000040261.30455.b6

• Crossref
Calhoun DA, . Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40:892−896. doi: 10.1161/01.hyp.0000040261.30455.b610.1161/01.HYP.0000040261.30455.B6)| false
• Search Google Scholar
• Export Citation

Hundemer GL, et al.. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: A retrospective cohort study. Lancet Diabetes Endocrinol 2018; 6:51−59. doi: 10.1016/S2213-8587(17)30367-4

• Crossref
Hundemer GL, . Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: A retrospective cohort study. Lancet Diabetes Endocrinol 2018; 6:51−59. doi: 10.1016/S2213-8587(17)30367-410.1016/S2213-8587(17)30367-4)| false
• Search Google Scholar
• Export Citation

Byrd JB, et al.. Primary aldosteronism: Practical approach to diagnosis and management. Circulation 2018; 138:823−835. doi: 10.1161/CIRCULATIONAHA.118.033597

• Crossref
Byrd JB, . Primary aldosteronism: Practical approach to diagnosis and management. Circulation 2018; 138:823−835. doi: 10.1161/CIRCULATIONAHA.118.03359710.1161/CIRCULATIONAHA.118.033597)| false
• Search Google Scholar
• Export Citation

Funder JW, et al.. The management of primary aldosteronism: Case detection, diagnosis, and treatment: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2016; 101:1889−1916. doi: 10.1210/jc.2015-4061

• Crossref
Funder JW, . The management of primary aldosteronism: Case detection, diagnosis, and treatment: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2016; 101:1889−1916. doi: 10.1210/jc.2015-406110.1210/jc.2015-4061)| false
• Search Google Scholar
• Export Citation

Whelton PK, et al.. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71:1269−1324. doi: 10.1161/HYP.0000000000000066

Whelton PK, . 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71:1269−1324. doi: 10.1161/HYP.0000000000000066)| false
• Search Google Scholar
• Export Citation

Jaffe G, et al.. Screening rates for primary aldosteronism in resistant hypertension: A cohort study. Hypertension 2020; 75:650−659. doi: 10.1161/HYPERTENSIONAHA.119.14359

• Crossref
Jaffe G, . Screening rates for primary aldosteronism in resistant hypertension: A cohort study. Hypertension 2020; 75:650−659. doi: 10.1161/HYPERTENSIONAHA.119.1435910.1161/HYPERTENSIONAHA.119.14359)| false
• Search Google Scholar
• Export Citation

Ruhle BC, et al.. Keeping primary aldosteronism in mind: Deficiencies in screening at-risk hypertensives. Surgery 2019; 165:221−227. doi: 10.1016/j.surg.2018.05.085

• Crossref
Ruhle BC, . Keeping primary aldosteronism in mind: Deficiencies in screening at-risk hypertensives. Surgery 2019; 165:221−227. doi: 10.1016/j.surg.2018.05.08510.1016/j.surg.2018.05.085)| false
• Search Google Scholar
• Export Citation

Sivarajah M, et al.. Adherence to consensus guidelines for screening of primary aldosteronism in an urban healthcare system. Surgery 2020; 167:211−215. doi: 10.1016/j.surg.2019.05.087

• Crossref
Sivarajah M, . Adherence to consensus guidelines for screening of primary aldosteronism in an urban healthcare system. Surgery 2020; 167:211−215. doi: 10.1016/j.surg.2019.05.08710.1016/j.surg.2019.05.087)| false
• Search Google Scholar
• Export Citation

Cohen JB, et al.. Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among U.S. veterans: A retrospective cohort study. Ann Intern Med [published online ahead of print December 29, 2020]. doi: 10.7326/M20-4873; https://www.acpjournals.org/doi/10.7326/M20-4873

Cohen JB, . Testing for primary aldosteronism and mineralocorticoid receptor antagonist use among U.S. veterans: A retrospective cohort study. Ann Intern Med [published online ahead of print December 29, 2020]. doi: 10.7326/M20-4873; https://www.acpjournals.org/doi/10.7326/M20-4873)| false
• Search Google Scholar
• Export Citation